CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer
This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with Bevacizumab plus Anti-PD1 Antibody as neoadjuvant therapy for locally recurrent colorectal cancer
Locally Recurrent Colorectal Cancer
DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Bevacizumab|DRUG: Tislelizumab
Objective response rate, Percentage of patients who achieve partial response (PR) or complete response (CR), 15 weeks|R0 resection rate, Percentage of patients who achieve R0 resection, 15 weeks|Pathological complete response rate, Percentage of patients who achieve pathological complete response (pCR) based on local investigator, 15 weeks|Tumor regression grade (TRG), 15 weeks|Incidence of Treatment-Related Adverse Events, Number of adverse events, Until 30 days after the last treatment
Surgical complications, Until 90 days after surgery|Quality of life score (QoL score), Assessment of life quality based on EORTC QLQ-C30, Until 30 days after the last treatment|Event free survival, Measure of time from study treatment to disease progression or death, Up to 3 years|Disease-free survival, Measure of time from the date of surgery to disease relapse or death, Up to 3 years|One-year or two-year disease-free survival rate, Percentage of patients who achieve disease-free survival lasting for more than one and two years respectively from the date of surgery, Up to 2 years|One-year or two-year overall survival rate, Percentage of patients who achieve survival for more than one and two years respectively from date of first dose, Up to 2 years
This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with Bevacizumab plus Anti-PD1 Antibody as neoadjuvant therapy for locally recurrent colorectal cancer